febuxostat has been researched along with potassium oxonate in 1 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (potassium oxonate) | Trials (potassium oxonate) | Recent Studies (post-2010) (potassium oxonate) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 132 | 7 | 111 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; Cai, Z; Chen, T; Huang, X; Mi, X; Shui, G; Wang, F | 1 |
1 trial(s) available for febuxostat and potassium oxonate
| Article | Year |
|---|---|
Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.
Topics: Actins; Animals; Cadherins; Caspases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Febuxostat; Fibronectins; Hyperuricemia; Inflammasomes; Interleukin-18; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Renal Insufficiency, Chronic; Uric Acid; Vimentin | 2022 |